Zdrowie i gospodarka · 03/07/2025
FDA Clears Path for SYNDROS (Dronabinol) Solution Approval
The FDA has determined that SYNDROS (dronabinol) solution, 5 mg/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs).